Mfg. of: Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 04.02.2023

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001
Scrip Code: 540359

<u>Sub: Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements)</u> Regulations, 2015.

Dear Sir,

With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Saturday, 11th February, 2023 at 12.30 PM inter alia to consider, approve the Unaudited Financial Results of the quarter and nine months ended 31st December, 2022 and to discuss any other matter with the permission of Board.

Under our letter dated 30th December, 2022, we had communicated closure of trading window in respect of the Company with immediate effect till 48 hours after public announcement of the Unaudited Financial Results for the quarter ended 31st December, 2022. Consequently, the Trading Window will remain closed till 13th February, 2023.

You are requested to kindly take the above information on your record.

Thanking you,

Yours faithfully,

For Parmax Pharma Limited

Dr. Umang Gosalia Managing Director